Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Flatt

Showing results (1-10 of 325) with videos related to

Pageof 33
Sort By:
Diabetes & Vascular Disease Research|July 27, 2007
Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?Peter R Flatt
World Journal of Diabetes|November 12, 2015
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disordersNigel Irwin, Peter R Flatt
Best Practice & Research. Clinical Endocrinology & Metabolism|September 15, 2009
Therapeutic potential for GIP receptor agonists and antagonistsNigel Irwin, Peter R Flatt
Current Opinion in Pharmacology|September 26, 2013
Enteroendocrine hormone mimetics for the treatment of obesity and diabetesNigel Irwin, Peter R Flatt
Peptides|November 8, 2024
Discovery of the bioactive form of glucagon-like peptide-1: An attempt to correct some misconceptionsJ Michael Conlon, Peter R Flatt
Peptides|February 8, 2018
Editorial: Newer peptide-based agents for treatment of patients with Type 2 diabetesPeter R Flatt, J Michael Conlon
Peptides|February 6, 2024
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetesClifford J Bailey, Peter R Flatt
Diabetologia|August 6, 2002
Report of the 11th EASD Islet Group meeting. Glasgow, UK, 13-15 September 2001Brian L Furman, Peter R Flatt
Diabetes Care|November 24, 2011
Emerging applications of metabolomic and genomic profiling in diabetic clinical medicineAine M McKillop, Peter R Flatt
Peptides|June 14, 2024
Editorial: The rise and rise of peptide therapeutics for obesity-diabetesPeter R Flatt, J Michael Conlon
Pageof 33

Showing results (1-10 of 325) with videos related to

Sort By:
Pageof 33
Diabetes & Vascular Disease Research|July 27, 2007
Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?Peter R Flatt
World Journal of Diabetes|November 12, 2015
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disordersNigel Irwin, Peter R Flatt
Best Practice & Research. Clinical Endocrinology & Metabolism|September 15, 2009
Therapeutic potential for GIP receptor agonists and antagonistsNigel Irwin, Peter R Flatt
Current Opinion in Pharmacology|September 26, 2013
Enteroendocrine hormone mimetics for the treatment of obesity and diabetesNigel Irwin, Peter R Flatt
Peptides|November 8, 2024
Discovery of the bioactive form of glucagon-like peptide-1: An attempt to correct some misconceptionsJ Michael Conlon, Peter R Flatt
Peptides|February 8, 2018
Editorial: Newer peptide-based agents for treatment of patients with Type 2 diabetesPeter R Flatt, J Michael Conlon
Peptides|February 6, 2024
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetesClifford J Bailey, Peter R Flatt
Diabetologia|August 6, 2002
Report of the 11th EASD Islet Group meeting. Glasgow, UK, 13-15 September 2001Brian L Furman, Peter R Flatt
Diabetes Care|November 24, 2011
Emerging applications of metabolomic and genomic profiling in diabetic clinical medicineAine M McKillop, Peter R Flatt
Peptides|June 14, 2024
Editorial: The rise and rise of peptide therapeutics for obesity-diabetesPeter R Flatt, J Michael Conlon
Pageof 33